Low-Dose Interleukin-2 Shows Promise in Slowing Motor Neurone Disease Progression in Landmark MIROCALS Trial
The MIROCALS clinical trial demonstrated that low-dose interleukin-2 (IL2LD) is safe and reduced the risk of death by over 40% in approximately 80% of motor neurone disease patients with lower levels of a specific biomarker.
© Copyright 2025. All Rights Reserved by MedPath